Conflicting reform decisions further confuse constitutionality

In the hot-bed of the Patient Protection and Affordable Care Act (PPACA) legal arena, two appeals court decisions were filed on Aug. 12 indicating the fractious nature of the constitutionality of the individual mandate provision.

In a two to one decision, the U.S. Court of Appeals for the 11th Circuit in State of Florida v. U.S. Department of Health and Human Services declared the individual mandate provision of the PPACA unconstitutional while upholding the constitutionality of the act.

“[T]he individual mandate was enacted as a regulatory penalty, not a revenue-raising tax, and cannot be sustained as an exercise of Congress’s power under the Taxing and Spending Clause,” the court wrote.

The Court found that the Act’s Medicaid expansion is constitutional. “Existing Supreme Court precedent does not establish that Congress’s inducements are unconstitutionally coercive, especially when the federal government will bear nearly all the costs of the program’s amplified enrollments,” the authors concluded.

The Florida suit included 26 states as plaintiffs who questioned the constitutionality of the PPACA.

The U.S. Court of Appeals for the 9th Circuit upheld the dismissal of Steve Baldwin and Pacific Justice Institute v. Kathleen Sebelius, a suit that also challenged the individual mandate provision. Citing that Baldwin, a former California legislator, and Pacific Justice Institute had not established a “genuine threat of imminent prosecution” nor a “justiciable pre-enforcement challenge to the act” that the court requires.

“In short, neither Baldwin nor the Institute has shown injury in fact, or a genuine threat of prosecution, sufficient to give them standing or make their challenge justiciable,” opinion author Pamela Ann Rymer concluded. Justiciability includes the limits on legal issues over which a court can exercise its judicial authority. It includes, but is not limited to, the legal concept of standing, which is used to determine if a party bringing the suit is appropriate for establishing whether an adverse issue exists.

The 11th Circuit Court's summary can be found here

The 9th Circuit Court's summary can be found here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.